New research done by teams from the Moffitt Cancer Center and Dana-Farber Cancer Institute are investigating the possibility that radiomics have the potential to improve precision medicine by non-invasive surgery! Check out the article, below, for more information.
Precision medicine has become the leading innovation of cancer treatment. Patients are routinely treated with drugs that are designed to target specific tumors and molecules. Despite the progress that has been made in targeted cancer therapies, the path has been slow and scientists have a long road ahead. In a collaborative project, researchers at the Moffitt Cancer Center and Dana-Farber Cancer Institute investigated the emerging field of radiomics has the potential to improve precision medicine by non-invasively assessing the molecular and clinical characteristics of lung tumors. Their work was published in the July 21 issue of eLIFE, a novel, emerging journal in biomedicine founded by National Academy members and Nobel Prize winners
Radiomics offers scientists and clinicians a novel way to analyze individual tumors for their biology, guide cancer treatment, and predict response to therapy. Virtually every cancer patient has their tumor imaged though computed tomography (CT), magnetic resonance (MRI), and/or positron emission tomography (PET) as standard-of-care. The images allow physicians to determine the stage and location of a tumor and guide treatment decisions. But with recent advances in computer generated data and models, these images are now being used in the field of radiomics to extract high-dimensional data that can be used to guide precision medicine. By using radiomics, scientists are able to objectively quantitate different features of tumors, such as intensity, shape, size and texture. These data can then be used in combination with genetic and clinical data to predict active biological pathways, clinical outcomes, and potential effective therapies.